300 related articles for article (PubMed ID: 21048992)
21. Change in the Oligomeric State of α-Synuclein Variants in Living Cells.
Fan HF; Chen WL; Chen YZ; Huang JW; Shen YX
ACS Chem Neurosci; 2022 Apr; 13(8):1143-1164. PubMed ID: 35394271
[TBL] [Abstract][Full Text] [Related]
22. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
[TBL] [Abstract][Full Text] [Related]
23. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
24. Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo.
Mbefo MK; Fares MB; Paleologou K; Oueslati A; Yin G; Tenreiro S; Pinto M; Outeiro T; Zweckstetter M; Masliah E; Lashuel HA
J Biol Chem; 2015 Apr; 290(15):9412-27. PubMed ID: 25657004
[TBL] [Abstract][Full Text] [Related]
25. Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.
Huang YR; Xie XX; Ji M; Yu XL; Zhu J; Zhang LX; Liu XG; Wei C; Li G; Liu RT
Neurobiol Dis; 2019 Apr; 124():202-217. PubMed ID: 30481547
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
27. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.
Cao S; Standaert DG; Harms AS
J Neuroinflammation; 2012 Nov; 9():259. PubMed ID: 23186369
[TBL] [Abstract][Full Text] [Related]
28. Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease.
Cardinale A; Calabrese V; de Iure A; Picconi B
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204581
[TBL] [Abstract][Full Text] [Related]
29. Nitrated alpha-synuclein and microglial neuroregulatory activities.
Reynolds AD; Kadiu I; Garg SK; Glanzer JG; Nordgren T; Ciborowski P; Banerjee R; Gendelman HE
J Neuroimmune Pharmacol; 2008 Jun; 3(2):59-74. PubMed ID: 18202920
[TBL] [Abstract][Full Text] [Related]
30. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
31. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro.
Rojanathammanee L; Murphy EJ; Combs CK
J Neuroinflammation; 2011 May; 8():44. PubMed ID: 21554732
[TBL] [Abstract][Full Text] [Related]
32. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
33. α-Synuclein Disrupts Vesicle Fusion by Two Mutant-Specific Mechanisms.
Yoo G; An HJ; Yeou S; Lee NK
Mol Cells; 2022 Nov; 45(11):806-819. PubMed ID: 36380732
[TBL] [Abstract][Full Text] [Related]
34. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.
Gao HM; Kotzbauer PT; Uryu K; Leight S; Trojanowski JQ; Lee VM
J Neurosci; 2008 Jul; 28(30):7687-98. PubMed ID: 18650345
[TBL] [Abstract][Full Text] [Related]
35. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice.
Earls RH; Menees KB; Chung J; Barber J; Gutekunst CA; Hazim MG; Lee JK
J Neuroinflammation; 2019 Dec; 16(1):250. PubMed ID: 31796095
[TBL] [Abstract][Full Text] [Related]
36. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.
Wislet-Gendebien S; Visanji NP; Whitehead SN; Marsilio D; Hou W; Figeys D; Fraser PE; Bennett SA; Tandon A
BMC Neurosci; 2008 Sep; 9():92. PubMed ID: 18808659
[TBL] [Abstract][Full Text] [Related]
38. Label-free detection of early oligomerization of α-synuclein and its mutants A30P/E46K through solid-state nanopores.
Li X; Tong X; Lu W; Yu D; Diao J; Zhao Q
Nanoscale; 2019 Mar; 11(13):6480-6488. PubMed ID: 30892349
[TBL] [Abstract][Full Text] [Related]
39. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
40. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
